Diplomatic Trade Capital Acquires Majority Stake in Turkish Pharmaceutical Company, Targets $300M IPO

Diplomatic Trade Capital has made a strategic investment in Farmakim ilaç Kimya Gida Ürünleri Üretim San ve Dis Tie A.S., a prominent Turkish pharmaceutical manufacturer, signaling significant expansion in the Middle Eastern healthcare sector. The transaction involves acquiring a 49% equity position, providing board-level oversight and commercial rights.

The joint venture aims to establish a cutting-edge bio-manufacturing facility in the UAE by the third quarter of 2025. This facility will specialize in biosynthetic therapies, regenerative compounds, and advanced life-extension pharmaceuticals targeting Gulf states and North African markets. The site will incorporate advanced technologies including AI-driven quality control and packaging aligned with European Union Good Manufacturing Practice standards.

With an anticipated initial public offering targeted for the fourth quarter of 2025, the newly formed group is currently being valued by a top-tier advisory firm. Preliminary projections suggest a potential IPO valuation around $300 million, supported by strong projected earnings, distribution rights across the Gulf Cooperation Council region, and proprietary therapeutic pipelines.

The investment, backed by Morgan Brookshire LLC, represents a significant transatlantic commitment to developing pharmaceutical infrastructure in the Gulf region. It positions Diplomatic Trade Ltd as a key player in regional life sciences consolidation and emerging market healthcare investments.

This strategic move highlights the growing importance of cross-border pharmaceutical investments and the increasing focus on precision medicine and biotechnology in emerging markets. The partnership aims to enhance pharmaceutical supply chain independence and drive innovation in healthcare infrastructure across the Middle East and North Africa region.